ArticleThe Journal of infectious diseases2019
Serological Evidence of Japanese Encephalitis Virus Circulation in Asian Children From Dengue-Endemic Countries.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A multiplex serological assay for quantification of arbovirus antibody kinetics and neutralizing antibodies.PLoS neglected tropical diseases · 2026Article
- NADFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Article
- Real-world safety profile of live attenuated Japanese encephalitis vaccine before and after the vaccine administration law.PloS one · 2025Article
- Article
- Japanese encephlu emergence in Australia: the potential population at risk.Annals of medicine and surgery (2012) · 2024Review
- Trends in emerging vector-borne viral infections and their outcome in children over two decades.Pediatric research · 2024Review
- Survey of mosquito species and mosquito-borne viruses in residential areas along the Sino-Vietnam border in Yunnan Province in China.Frontiers in microbiology · 2023Article
- Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.Human vaccines & immunotherapeutics · 2022Article
- Seroepidemiological study of Japanese encephalitis virus in Chiang Mai: Immunity and susceptibility 28 years after introduction of a vaccination programme.PLoS neglected tropical diseases · 2022Article
- Health system preparedness & community participation in Japanese encephalitis/acute encephalitis syndrome (JE/AES) prevention in a tribal district of Odisha, India.The Indian journal of medical research · 2021Article
- Essential Oils ofPlants (Basel, Switzerland) · 2020Article
- A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies.Vaccines · 2020Article
- Article
- Risk perception of health problems among travelers visiting a travel clinic in Bangkok, Thailand.Tropical diseases, travel medicine and vaccines · 2020Article
- Identification of Immune Responses to Japanese Encephalitis Virus Specific T Cell Epitopes.Frontiers in public health · 2020Article
- 'More than devastating'-patient experiences and neurological sequelae of Japanese encephalitis§.Journal of travel medicine · 2019Article
- Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading.Pathogens (Basel, Switzerland) · 2019Review
- Analysis of Zika virus neutralizing antibodies in normal healthy Thais.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Japanese encephalitis virus (JEV) is a zoonotic, mosquito-borne flavivirus, distributed across Asia. Infections are mostly mild or asymptomatic, but symptoms include neurological disorders, sequelae, and fatalities. Data to inform control strategies are limited due to incomplete case reporting. Methods: We used JEV serological data from a multicountry Asian dengue vaccine study in children aged 2-14 years to describe JEV endemicity, measuring antibodies by plaque reduction neutralization test (PRNT50). Results: A total 1479 unvaccinated subjects were included. A minimal estimate of pediatric JEV seroprevalence in dengue-naive individuals was 8.1% in Indonesia, 5.8% in Malaysia, 10.8% in the Philippines, and 30.7% in Vietnam, translating to annual infection risks varying from 0.8% (in Malaysia) to 5.2% (in Vietnam). JEV seroprevalence and annual infection estimates were much higher in children with history of dengue infection, indicating cross-neutralization within the JEV PRNT50 assay. Conclusions: These data confirm JEV transmission across predominantly urban areas and support a greater emphasis on JEV case finding, diagnosis, and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.